Literature DB >> 25305660

Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study.

F De Seta1, F Parazzini2, R De Leo3, R Banco3, G P Maso3, D De Santo3, A Sartore3, G Stabile3, S Inglese3, M Tonon3, S Restaino3.   

Abstract

BACKGROUND: Recurrence is a frequent complaint of patients with vulvovaginal candidiasis (VVC). Although the pathogenesis of VVC remains a controversial issue, disruption of the balance between the vaginal microbiota may facilitate overgrowth by Candida. Some probiotic bacterial strains can suppress Candida albicans; Lactobacillus plantarum P17630 is able to attach to vaginal epithelial cells and significantly reduce the adhesion of C. albicans.
OBJECTIVE: To evaluate the effect of the application of Lactobacillus plantarum P17630 in restoring the vaginal microbiota and prevention of relapses among women with acute VVC undergoing conventional (azole) local and main therapy.
METHODS: Retrospective comparative study. We recruited 89 women with a diagnosis of VVC, who were placed into two groups on the basis of reported treatment. The control group was treated with a daily dose of 2% clotrimazole vaginal cream at bedtime for 3 days, followed by vaginal application of a capsule containing lubricant once a day for 6 days and then once a week for another 4 weeks. The probiotic group was treated with the same azole-based protocol but followed by vaginal application of a capsule containing Lactobacillus plantarum P17630 (>10₈ CFU) once a day for 6 days and then once a week for another 4 weeks beginning the day following clotrimazole discontinuation. Clinical and diagnostic patterns were monitored for three months of follow-up.
RESULTS: At the end of study the probiotic-treated women showed a statistically significant increase in Lactobacillus values "+++" (80% versus 40%, p<0.001) and a better subjective resolution of symptoms such as vaginal discomfort described as burning or itching (90% versus 67.5%, p<0.03). Among controls there was a non-significant increase at 3 months of recurrence of infection, but a significant increase of women with value of pH=5 or >5.
CONCLUSION: Although the results of different studies are controversial, most have suggested use of probiotics in the prevention or treatment of VVC, and no adverse effects have been reported. Our data with L. plantarum P17630 (Gyno-Canesflor - Bayer) confirm the role of this specific strain as a potential empirical preventive agent for reducing vaginal discomfort after conventional treatment of acute VVC and shifting the vaginal milieu toward a predominance of lactobacilli with an improvement of the vaginal pH value.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Lactobacillus plantarum P17630; Probiotic; Vulvovaginal candidiasis

Mesh:

Substances:

Year:  2014        PMID: 25305660     DOI: 10.1016/j.ejogrb.2014.09.018

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  27 in total

1.  Impact of Probiotic SYNBIO(®) Administered by Vaginal Suppositories in Promoting Vaginal Health of Apparently Healthy Women.

Authors:  Maria Cristina Verdenelli; Cinzia Cecchini; Maria Magdalena Coman; Stefania Silvi; Carla Orpianesi; Giuliana Coata; Alberto Cresci; Gian Carlo Di Renzo
Journal:  Curr Microbiol       Date:  2016-06-21       Impact factor: 2.188

2.  Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).

Authors:  Alex Farr; Isaak Effendy; Brigitte Frey Tirri; Herbert Hof; Peter Mayser; Ljubomir Petricevic; Markus Ruhnke; Martin Schaller; Axel P A Schäfer; Birgit Willinger; Werner Mendling
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-04-14       Impact factor: 2.915

Review 3.  Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health.

Authors:  Mariya I Petrova; Elke Lievens; Shweta Malik; Nicole Imholz; Sarah Lebeer
Journal:  Front Physiol       Date:  2015-03-25       Impact factor: 4.566

4.  Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity.

Authors:  Carola Parolin; Antonella Marangoni; Luca Laghi; Claudio Foschi; Rogers Alberto Ñahui Palomino; Natalia Calonghi; Roberto Cevenini; Beatrice Vitali
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

5.  Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504).

Authors:  S Palacios; J Espadaler; J M Fernández-Moya; C Prieto; N Salas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-09       Impact factor: 3.267

Review 6.  Mechanisms and therapeutic effectiveness of lactobacilli.

Authors:  Alessandro Di Cerbo; Beniamino Palmieri; Maria Aponte; Julio Cesar Morales-Medina; Tommaso Iannitti
Journal:  J Clin Pathol       Date:  2015-11-17       Impact factor: 3.411

Review 7.  Probiotics in the Prevention and Treatment of Postmenopausal Vaginal Infections: Review Article.

Authors:  Jun-Mo Kim; Yoo Jin Park
Journal:  J Menopausal Med       Date:  2017-12-29

8.  Therapeutic activity of a Saccharomyces cerevisiae-based probiotic and inactivated whole yeast on vaginal candidiasis.

Authors:  Eva Pericolini; Elena Gabrielli; Nathalie Ballet; Samuele Sabbatini; Elena Roselletti; Amélie Cayzeele Decherf; Fanny Pélerin; Eugenio Luciano; Stefano Perito; Peter Jüsten; Anna Vecchiarelli
Journal:  Virulence       Date:  2016-07-19       Impact factor: 5.882

Review 9.  Health-Promoting Properties of Lactobacilli in Fermented Dairy Products.

Authors:  Yantyati Widyastuti; Andi Febrisiantosa; Flavio Tidona
Journal:  Front Microbiol       Date:  2021-05-21       Impact factor: 5.640

Review 10.  The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis.

Authors:  Silke Baldewijns; Mart Sillen; Ilse Palmans; Paul Vandecruys; Patrick Van Dijck; Liesbeth Demuyser
Journal:  Front Microbiol       Date:  2021-07-02       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.